[go: up one dir, main page]

FR2819263B1 - Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740 - Google Patents

Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740

Info

Publication number
FR2819263B1
FR2819263B1 FR0100275A FR0100275A FR2819263B1 FR 2819263 B1 FR2819263 B1 FR 2819263B1 FR 0100275 A FR0100275 A FR 0100275A FR 0100275 A FR0100275 A FR 0100275A FR 2819263 B1 FR2819263 B1 FR 2819263B1
Authority
FR
France
Prior art keywords
macrophages
maturation
activation
dendritic cells
dendritic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0100275A
Other languages
English (en)
Other versions
FR2819263A1 (fr
Inventor
Dominique Rigal
Daniel Masseau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LCO SANTE
Original Assignee
LCO SANTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0100275A priority Critical patent/FR2819263B1/fr
Application filed by LCO SANTE filed Critical LCO SANTE
Priority to PCT/FR2002/000088 priority patent/WO2002055676A2/fr
Priority to CA002434399A priority patent/CA2434399A1/fr
Priority to AU2002229866A priority patent/AU2002229866A1/en
Priority to JP2002556726A priority patent/JP2004527230A/ja
Priority to EP02710965A priority patent/EP1352053A2/fr
Publication of FR2819263A1 publication Critical patent/FR2819263A1/fr
Application granted granted Critical
Publication of FR2819263B1 publication Critical patent/FR2819263B1/fr
Priority to US10/616,868 priority patent/US20040152191A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR0100275A 2001-01-10 2001-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740 Expired - Fee Related FR2819263B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0100275A FR2819263B1 (fr) 2001-01-10 2001-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
CA002434399A CA2434399A1 (fr) 2001-01-10 2002-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
AU2002229866A AU2002229866A1 (en) 2001-01-10 2002-01-10 Method for processing dendritic cells and for activating macrophages with ru 41740
JP2002556726A JP2004527230A (ja) 2001-01-10 2002-01-10 Ｒｕ４１７４０を用いた樹状細胞の成熟化及びマクロファージの活性化方法
PCT/FR2002/000088 WO2002055676A2 (fr) 2001-01-10 2002-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
EP02710965A EP1352053A2 (fr) 2001-01-10 2002-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
US10/616,868 US20040152191A1 (en) 2001-01-10 2003-07-10 Process for the maturation of dendritic cells and for the activation of macrophages with RU 41740

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0100275A FR2819263B1 (fr) 2001-01-10 2001-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740

Publications (2)

Publication Number Publication Date
FR2819263A1 FR2819263A1 (fr) 2002-07-12
FR2819263B1 true FR2819263B1 (fr) 2003-04-11

Family

ID=8858661

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0100275A Expired - Fee Related FR2819263B1 (fr) 2001-01-10 2001-01-10 Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740

Country Status (7)

Country Link
US (1) US20040152191A1 (fr)
EP (1) EP1352053A2 (fr)
JP (1) JP2004527230A (fr)
AU (1) AU2002229866A1 (fr)
CA (1) CA2434399A1 (fr)
FR (1) FR2819263B1 (fr)
WO (1) WO2002055676A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
FR2824334B1 (fr) * 2001-05-03 2003-10-10 Coletica Procede pour tester une substance eventuellement active dans le domaine de la lipolyse et son utilisation principalement cosmetique
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
CN102325790A (zh) 2008-12-03 2012-01-18 西马生物医学计划公司 应用酚可溶性调控蛋白研制疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808897A1 (fr) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules Cellules présentant l'antigène, procédé de leur fabrication et leur utilisation comme des vaccins cellulaires
WO1999050391A1 (fr) * 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Cellules derivees de monocytes stimules, leur preparation et leurs utilisations

Also Published As

Publication number Publication date
AU2002229866A1 (en) 2002-07-24
JP2004527230A (ja) 2004-09-09
US20040152191A1 (en) 2004-08-05
EP1352053A2 (fr) 2003-10-15
WO2002055676A2 (fr) 2002-07-18
FR2819263A1 (fr) 2002-07-12
WO2002055676A3 (fr) 2003-01-03
CA2434399A1 (fr) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2001296703A1 (en) Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
DE60034023D1 (de) Verfahren zur herstellung keramischer kronen und bausatz zu deren herstellung
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU1917201A (en) Amide therapeutics and methods for treating inflammatory bowel disease
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL153883A0 (en) Improved methods and processes for iodine disinfection
IL145301A0 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
IL155433A0 (en) Treatment of t cell disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
EP1581206A4 (fr) Traitement de troubles inflammatoires par des 2,3-benzodiazepines
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
FR2819263B1 (fr) Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2002332856A1 (en) Methods for producing ex vivo models for inflammatory disease and uses thereof
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
EP1453387A4 (fr) Procedes de production de tablettes de gomme a macher et tablettes de gomme a macher ainsi produites
AU2001261519A1 (en) Methods of affecting laminin 5 processing
ID26858A (id) Proses memproduksi hidrogen peroksida
IL155874A0 (en) Treatment of anxiety disorders
GB0123181D0 (en) Production of formaldehyde from CH 4 and H 2 S

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20070930